“…[6] Among these, epidermal growth factor (EGF) has been shownt op articipate in many types of solidt umour,i ncluding heada nd neck, breast, colon,o varian, and non-small-celll ung cancer. [7,8] To perform its function, EGF binds with high affinity (K D = 1.9 nm) [9] to its membrane receptor (EGFR), [10] andt his triggers intracellular events that lead to uncontrolled cell growth, tumour invasion, and metastasis. [8] Therefore, the EGF-EGFR pathway has become am ain focus for selective chemotherapeutic intervention, and as ar esult, two classes of EGFR inhibitors have been clinically approved, namely,m onoclonal antibodies [11] (cetuximab, panitumumab), which target the extracellulard omain of EGFR,a nd small-molecule kinase inhibitors [12] (gefitinib, erlotinib), which block the intracellular phosphorylation of the receptor.…”